Application of PRMT6 inhibitor in preparation of medicine for treating thyroid-associated ophthalmopathy
By using the PRMT6 inhibitor EPZ020411, targeting the mouse model of TAO, inhibiting orbital adipose tissue hyperplasia and macrophage-mediated lipidogenesis differentiation, the problem of instability in the efficacy and major side effects of existing TAO treatment methods was solved, and significantly improved Ocular symptoms and hyperthyroidism manifestations in TAO mice.
Patent Information
- Application Number
- CN202410847061.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-27
- Publication Date
- 2024-11-08
AI Technical Summary
The existing TAO treatment methods are limited, the efficacy of mainstream drugs is unstable and have great side effects. Surgical treatment cannot fully restore the patient's appearance and visual function, and there is a lack of effective new treatment methods.
Using PRMT6 inhibitor EPZ020411 as an active ingredient drug, the drug was administered to a mouse model of TAO by inhibiting the protein methylation function of PRMT6, significantly inhibiting orbital adipose tissue hyperplasia and macrophage-mediated pro-adipocyte adipogenesis differentiation. , improve eye symptoms.
Significantly improved the eye symptoms of TAO mice, including reducing orbital adipose tissue hyperplasia, reducing serum TT4 levels, reducing thyroid gland volume and reducing inflammation, improving the quality of life and visual function of mice.
Smart Images

Figure CN118903115A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to the use of a PRMT6 inhibitor in the preparation of a drug for treating thyroid-related eye diseases. Background Art
[0002] Thyroid-associated ophthalmopathy (TAO), also known as Graves' ophthalmopathy, is a common orbital disease that can cause disability and blindness. Patients may experience disfiguring eye changes (such as proptosis and eyelid retraction), orbital inflammation (such as redness and swelling of the eyelids and conjunctiva), ocular motility disorders (strabismus, diplopia), and visual dysfunction (visual field defects, decreased vision, and even blindness), leading to loss of work ability, reduced quality of life, and impaired mental health.
[0003] Currently, the clinical treatments for TAO are very limited. Mainstream drugs include glucocorticoids and immunosuppressants, which have different efficacy from person to person, have large side effects, and are prone to relapse. Tetumumab, approved for marketing in the United States, once brought hope for TAO treatment, but its high price and obvious systemic side effects, including up to 50% permanent hearing loss and hyperglycemia, have greatly limited its clinical application. Surgical treatments, including orbital decompression and strabismus correction, cannot completely restore the patient's appearance and normal visual function. Therefore, there is an urgent need to develop new TAO treatments to solve this clinical problem.
[0004] Protein arginine methyl transferases (PRMTs) are a class of enzymes that are widely present in cells and regulate protein methylation modification. They regulate the biological activity of target proteins by transferring the methyl group on the S-adenosylmethionine (SAM) group to the guanidinium nitrogen atom on the arginine residue of the target protein, thereby participating in physiological activities in the body. The arginine N-methyltransferase 6 (PRMT6) gene is located on chromosome 1p13.3. EPZ020411 is a small molecule inhibitor of PRMT6 that can selectively inhibit the protein arginine methylation function of PRMT6 and has good in vivo bioavailability. Literature has reported the role of EPZ020411 in the treatment of glioblastoma, neuropathic pain, and hearing loss. At present, there are no reports on the role of EPZ020411 in the treatment of thyroid-related eye diseases. Summary of the invention
[0005] The present invention discovers for the first time a new use of PRMT6 inhibitors, which can be used to treat thyroid-related eye diseases.
[0006] The specific technical solutions of the present invention are as follows:
[0007] Application of PRMT6 inhibitors in the preparation of drugs for the treatment of thyroid-related eye diseases.
[0008] In a specific example of the present invention, the PRMT6 inhibitor is a compound having the following structure or a pharmaceutically acceptable salt thereof:
[0009]
[0010] The pharmaceutically acceptable salts may be common organic or inorganic acid salts, such as hydrochlorides, sulfates, phosphates, nitrates, and the like.
[0011] The drug contains a PRMT6 inhibitor as an active ingredient and may further include a pharmaceutically acceptable carrier.
[0012] The drug can be an oral preparation or an injectable preparation for systemic administration.
[0013] In the embodiment of the present invention, the dosage for TAO model mice is 10 mg / kg, which is equivalent to 10 mg / kg for humans.
[0014] Advantages of the present invention:
[0015] The present invention uses macrophages and PRMT6 in the orbital tissue of mice with thyroid-associated eye disease as therapeutic targets, and is an innovative treatment method different from traditional treatment based on the pathogenesis of TAO.
[0016] The research results of the present invention show that the PRMT6 inhibitor EPZ020411 can significantly inhibit the hyperplasia of orbital adipose tissue in TAO mice, and inhibit the adipogenic differentiation of preadipocytes through macrophages, thereby significantly improving the eye symptoms caused by TAO. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Results of the improvement of hyperthyroidism symptoms in TAO mice by PRMT6 inhibitor EPZ020411. (A: Schematic diagram of mouse grouping; B: TAO mouse modeling cycle (↑: intramuscular injection of Ad-TSHR; *: eye photography and MRI, serum ELISA analysis, thyroid and orbital pathological evaluation); C: mouse body weight changes (n=10); D: mouse serum TT4 level detection (n=10); E: mouse serum TRAb level detection (n=10); F: mouse thyroid gross photography and volume evaluation (n=3); G: mouse thyroid tissue section HE and CD3 staining (scale bar: 20μm). ns: no significance, **p<0.01, ****p<0.0001).
[0018] Figure 2The results show that the PRMT6 inhibitor EPZ020411 improves the eye phenotype of TAO mice. (A: Photos of mouse eyes; B: T2 phase of mouse cranial MRI (red arrows indicate the fibrotic area of the mouse eyelids, white arrows indicate the fibrotic area of the mouse orbital tissue); C and D: HE staining to evaluate the orbital fat area of the mouse (blue area is adipose tissue, scale bar: 200μm, n≥5); E and F: Masson staining to evaluate the degree of orbital tissue fibrosis of the mouse (scale bar: 20μm, n≥5). ns: no significance, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).
[0019] Figure 3 PRMT6 inhibitor EPZ020411 inhibits macrophage-mediated adipogenic differentiation of 3T3-L1. (A: Establishment of Transwell co-culture system; B and C: Oil red staining to detect the effect of EPZ020411 on macrophage-mediated adipogenic differentiation of 3T3-L1 (scale bar: 10 μm); D: qPCR to detect the effect of EPZ020411 on the expression of macrophage-mediated adipogenic differentiation markers of 3T3-L1). DETAILED DESCRIPTION
[0020] The specific steps of the present invention are described below by way of examples, but are not limited to the examples.
[0021] The terms used in the present invention, unless otherwise specified, generally have the meanings commonly understood by those of ordinary skill in the art.
[0022] The present invention is further described in detail below in conjunction with specific examples and with reference to data. It should be understood that these embodiments are only for illustrating the present invention and are not intended to limit the scope of the present invention in any way.
[0023] In the following examples, various processes and methods not described in detail are conventional methods well known in the art.
[0024] Example 1 Therapeutic effect of EPZ020411 on TAO mouse model
[0025] BALB / c mice (N000020) were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. (China), and human TSHR A subunit adenovirus (Ad-TSHR-289) was synthesized by Hanheng Biotechnology Co., Ltd. (China). The TAO mouse model was constructed according to the literature (Zhang M, Ding X, Wu LP, He MQ, Chen ZY, Shi BY, Wang Y. A Promoting Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit. Thyroid. 2021; 31(4): 638-648).
[0026] The levels of total thyroid hormone (TT4) and anti-thyrotropin receptor antibody (TRAb) in mouse serum were detected by corresponding ELISA kits (MB-5849A and MB-3150A, Jiangsu Enzyme Biotechnology Co., Ltd., China). The mouse thyroid tissue and orbital tissue were fixed, dehydrated, embedded in paraffin, and sliced with a thickness of 5 μm. HE stain (G1005), anti-CD3 antibody (GB13014), immunohistochemistry kit (G1215), and Masson stain (G1006) used for pathological staining of sections were purchased from Wuhan Sewell Biotechnology Co., Ltd. (China).
[0027] (1) Preparation of test solution
[0028] 5 mg of EPZ020411 (1700663-41-7, MedChemExpress, USA) was dissolved in 5 ml of sterile PBS to a final concentration of 1 mg / ml, and the mixture was shaken thoroughly to completely dissolve the drug.
[0029] (2) Testing process
[0030] A total of 30 6-week-old BALB / c female mice were randomly divided into three groups: control group (NC), modeling + no drug group (TAO + PBS), modeling + drug group (TAO + EPZ), with 10 mice in each group ( Figure 1 A). The mice in the model group were injected with human TSHR A subunit adenovirus into the leg muscles regularly, with the virus amount of 5×10 9 pfu, a total of 9 injections; the first 3 injections were 3 weeks apart, the next 6 injections were 4 weeks apart, and the modeling period was 34 weeks ( Figure 1 B). Starting from 11 weeks after modeling, the mice in the modeling + drug administration group were intraperitoneally injected with the test solution at a dose of 10 mg / kg, once a week until the modeling was completed; the mice in the modeling + non-drug administration group were intraperitoneally injected with the same volume of sterile PBS.
[0031] During the test, the mice in each group were weighed regularly, and their status and eye manifestations were observed. After the model was established, the mouse serum was collected to detect the levels of TT4 and TRAb, and the mice were photographed and MRI was performed on their eyes. The mice were then euthanized and the thyroid and orbital tissues were taken for pathological analysis.
[0032] (3) Test results
[0033] The results of mouse weight monitoring showed that as the modeling period prolonged, the weight of mice in the modeling + non-drug group was significantly reduced compared with the control group, while the weight of mice in the drug group was significantly increased compared with the non-drug group ( Figure 1 C). ELISA results showed that the serum TT4 and TRAb levels of mice in the modeling + non-drug group were significantly higher than those in the control group, while the serum TT4 level of mice in the drug group was significantly lower than that in the non-drug group, and there was no significant difference in TRAb level ( Figure 1 D and 1E). In addition, the thyroid volume of mice in the modeling + non-drug group was significantly increased compared with the control group, while the thyroid volume of mice in the drug group was significantly reduced compared with the non-drug group ( Figure 1 F). Thyroid pathological staining results showed that the thyroid follicles of mice in the modeling + non-drug group were hyperplastic and CD3 positive cells were significantly infiltrated compared with the control group, while the above situation of mice in the drug group was significantly alleviated compared with the non-drug group ( Figure 1 G). The above results suggest that EPZ020411 can significantly improve the hyperthyroidism symptoms of TAO mice, including weight loss, increased serum TT4 levels, thyroid enlargement, follicular hyperplasia, and inflammatory infiltration.
[0034] Eye photos showed that the mice in the modeling + non-drug group had significant protrusion of the eyeball, thickened eyelids, and periocular hemorrhage and inflammation symptoms, while the above symptoms of the mice in the drug group were improved ( Figure 2 A). MRI results showed that the mice in the modeling + non-drug group had significant eyeball proptosis (red arrow) and hyperplasia of orbital fat tissue (white arrow), while the above conditions of the mice in the drug-treated group improved ( Figure 2 B). HE staining of mouse orbital tissue sections showed that the orbital fat tissue area of mice in the modeling + non-drug group increased, while the orbital fat tissue area of mice in the drug group decreased ( Figure 2 C and 2D). In summary, EPZ020411 successfully inhibited the proliferation of orbital adipose tissue in TAO mice and improved the ocular symptoms of TAO mice.
[0035] Example 2 Effect of EPZ020411 on macrophage-mediated adipogenic differentiation of 3T3-L1 preadipocytes
[0036] (1) Test materials
[0037] 3T3-L1 mouse embryonic fibroblasts (ZQ0089) were purchased from Shanghai Zhongqiao Xinzhou Biotechnology Co., Ltd. (China) and cultured in DMEM high glucose (11965118, Gibco, USA) + 10% FBS medium (10099158, Gibco) at 37°C, 5% CO2 incubator. BMDM were extracted from the bone marrow of 6-8 week old male BALB / c mice (N000020, Jiangsu Jicui Yaokang Biotechnology Co., Ltd.), and the red blood cells were lysed and placed in a 37°C, 5% CO2 incubator for 4-6 hours. The non-adherent cells were taken and induced to differentiate in DMEM high glucose + 10% FBS + 20ng / ml M-CSF (CB34, Suzhou Jinan Protein Technology Co., Ltd., China) induction medium, and then induced to differentiate in a 37°C, 5% CO2 incubator for 5 days before subsequent experiments.
[0038] IBMX (I8450), dexamethasone (D8040), insulin (I8040), and Oil Red O staining kit (G1262) were purchased from Beijing Solebow Technology Co., Ltd. (China).
[0039] Test solution: Dissolve 5 mg EPZ020411 (1700663-41-7, MedChemExpress) in 0.19 ml sterile PBS to a final concentration of 50 mM and shake thoroughly to dissolve the drug completely.
[0040] (2) Testing process
[0041] 3T3-L1 cells and BMDM cells were co-cultured in a Transwell co-culture system (CLS3378, Corning, USA). BMDM cells treated with EPZ or PBS were placed on the upper layer, and 3T3-L1 cells were placed on the lower layer ( Figure 3 A). During the co-culture period, 3T3-L1 cells were induced to differentiate: after the cells were grown to confluence in normal growth medium (DMEM high glucose + 10% FBS) for 2-3 days, the medium was replaced with MDI induction medium (DMEM high glucose + 10% FBS + 0.5mM IBMX + 1μM dexamethasone + 10μg / ml insulin) for differentiation induction. After 2 days, the medium was replaced with differentiation medium (DMEM high glucose + 10% FBS + 10μg / ml insulin) to continue differentiation. After 2 days of differentiation, the medium was replaced with normal growth medium. After that, the medium was changed approximately every 72 hours to observe the synthesis of cell lipid droplets, and differentiation was terminated on the 16th day. Cells were stained with oil red to detect lipid droplet formation, and qPCR was used to detect the expression of adipogenic markers (FABP4, C / EBPα, PPARγ).
[0042] FABP4:
[0043] Forward primer: 5′TGAAATCACCGCAGACGACAGG3′;
[0044] Reverse primer: 5'GCTTGTCACCATCTCGTTTTCTC3'.
[0045] C / EBPα:
[0046] Forward primer: 5′GCAAAGCCAAGAAGTCGGTGGA3′;
[0047] Reverse primer: 5'CCTTCTGTTGCGTCTCCACGTT3'.
[0048] PPARγ:
[0049] Forward primer: 5′ATGGTTGACACAGAGATGC3′;
[0050] Reverse primer: 5'GAATGCGAGTGGTCTTCC3'.
[0051] qPCR amplification conditions: Step 1: 95°C for 30 seconds, 1 cycle; Step 2: 95°C for 10 seconds + 60°C for 30 seconds, 40 cycles; Step 3: Melting curve.
[0052] (3) Test results
[0053] Oil red staining of co-cultured 3T3-L1 cells showed that lipid droplet production in 3T3-L1 cells co-cultured with BMDM cells treated with EPZ020411 was reduced ( Figure 3 B and 3C). qPCR results showed that the expression of adipogenic markers (FABP4, C / EBPα, PPARγ) in 3T3-L1 cells co-cultured with BMDM cells treated with EPZ020411 was downregulated ( Figure 3 D). In summary, EPZ020411 can inhibit macrophage-mediated adipogenic differentiation of 3T3-L1 cells.
Claims
1. Application of PRMT6 inhibitors in the preparation of drugs for the treatment of thyroid-related eye diseases.
2. The use according to claim 1, characterized in that The PRMT6 inhibitor is a compound having the following structure or a pharmaceutically acceptable salt thereof:
3. The use according to claim 1, characterized in that The drug has a PRMT6 inhibitor as an active ingredient.
4. The use according to claim 1, characterized in that The medicine is an oral preparation or an injection preparation.
5. The use according to claim 1, characterized in that The dosage of the drug PRMT6 inhibitor is 10 mg / kg.
Citation Information
Patent Citations
Method and apparatus for improved resolution chromatography
US10099158B2
Cited By
Use of prmt6 inhibitors in the manufacture of a medicament for treating a retinal vascular damaging disease
CN122998351A
